Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30125359 | 1.00 | GABRA1 (0.54) | GABRA1GABRB2HSD17B3HTTTSHR | |
| SCHEMBL29619308 | 0.92 | KDM4E (0.58) | GABRA1GABRB2HSD17B3HTTTSHR | |
| SCHEMBL5440917 | 0.92 | KDM4E (0.58) | GABRA1GABRB2HSD17B3HTTTSHR | |
| SCHEMBL15470522 | 0.92 | GABRA1 (0.49) | GABRA1GABRB2HSD17B3HTTTSHR | |
| SCHEMBL4932617 | 0.92 | KDM4E (0.58) | GABRA1GABRB2HSD17B3HTTTSHR | |
| SCHEMBL5444639 | 0.90 | KDM4E (0.57) | GABRA1GABRB2HSD17B3HTTTSHR | |
| SCHEMBL29291671 | 0.90 | MAPT (0.53) | GABRA1GABRB2HSD17B3HTTTSHR | |
| SCHEMBL5444333 | 0.90 | KDM4E (0.57) | GABRA1GABRB2HSD17B3HTTTSHR | |
| SCHEMBL5436833 | 0.90 | KDM4E (0.57) | GABRA1GABRB2HSD17B3HTTTSHR | |
| SCHEMBL5436539 | 0.90 | KDM4E (0.57) | GABRA1GABRB2HSD17B3HTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115469039-A | Butylphthalide and related substance detection method thereof | 成都施贝康生物医药科技有限公司 | 2022-12-13 | — | — | CN | claimed |
| CN-115453014-A | Detection method of butylphthalide and related substances thereof | 成都施贝康生物医药科技有限公司 | 2022-12-09 | — | — | CN | claimed |
| CN-115469039-A | Butylphthalide and related substance detection method thereof | 成都施贝康生物医药科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-115453014-A | Detection method of butylphthalide and related substances thereof | 成都施贝康生物医药科技有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-8129545-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129545-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7982048-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-6855826-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040110692-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2004-06-10 | — | — | US | disclosed |
| US-6664420-B2 | For therapy of hypertension, type 2 insulin-resistant diabetes mellitus, ecalmpsia and preeclampsia | MAGNESIUM DIAGNOSTICS, INC. | 2003-12-16 | — | — | US | disclosed |
| EP-1355638-A2 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | Magnesium Diagnostics, Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030040625-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2003-02-27 | — | — | US | disclosed |
| US-6455734-B1 | ADMINISTERING PHENYLGLYCINAMIDE(N-2,4-DIAMYLPENTANOIC ACID AMIDE) AS HYPOTENSIVE AGENTS FOR PROPHYLAXIS OF INSULIN RESISTANCE, ECLAMPSIA AND SENSITIVITY TO BLOOD METAL CONCENTRATIONS | MAGNESIUM DIAGNOSTICS, INC. | 2002-09-24 | — | — | US | disclosed |
| WO-2002011714-A2 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| EP-0283359-B1 | PROCESS FOR THE PREPARATION OF KETONES | SOCIETE NATIONALE ELF AQUITAINE (FR) | 1990-09-12 | — | — | EP | disclosed |
| EP-0283359-A1 | Process for the preparation of ketones | SOCIETE NATIONALE ELF AQUITAINE (FR) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110692-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MCU | GABRA1 679/4885GABRB2 849/4885HSD17B3 797/4885 |
| US-20030040625-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | ECE1, PLPBP, ECE2 | GABRA1 798/4885GABRB2 944/4885HSD17B3 816/4885 |
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | PLPBP, ECE1, MCU | GABRA1 679/4885GABRB2 849/4885HSD17B3 797/4885 |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | PLPBP, ECE1, MCU | GABRA1 679/4885GABRB2 849/4885HSD17B3 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.